Bristol Myers Squibb Company $BMY Position Raised by Czech National Bank

Czech National Bank lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 3.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 536,798 shares of the biopharmaceutical company’s stock after acquiring an additional 19,839 shares during the period. Czech National Bank’s holdings in Bristol Myers Squibb were worth $28,955,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Harbor Capital Advisors Inc. grew its holdings in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares in the last quarter. KERR FINANCIAL PLANNING Corp acquired a new stake in Bristol Myers Squibb in the 3rd quarter valued at approximately $35,000. JPL Wealth Management LLC bought a new stake in Bristol Myers Squibb during the 3rd quarter valued at $36,000. Finally, Total Investment Management Inc. bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at $38,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Trading Up 2.7%

Bristol Myers Squibb stock opened at $58.94 on Thursday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The firm’s 50 day moving average price is $58.69 and its two-hundred day moving average price is $52.06. The firm has a market cap of $120.02 billion, a price-to-earnings ratio of 17.08, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the previous year, the firm earned $1.67 earnings per share. The business’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Analysts Set New Price Targets

BMY has been the topic of a number of recent analyst reports. Leerink Partners lifted their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. The Goldman Sachs Group restated a “neutral” rating and set a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. UBS Group reaffirmed a “buy” rating and issued a $70.00 price target on shares of Bristol Myers Squibb in a research note on Friday, March 6th. HSBC raised their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Finally, Truist Financial set a $65.00 price target on Bristol Myers Squibb in a research note on Wednesday, December 3rd. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average target price of $61.41.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.